Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Does metformin use effect overall survival for patients with pancreatic cancer?
Authors
Ravi Ramjeesingh
Division of Medical Oncology, Nova Scotia Cancer Center, Dalhousie University, Halifax, NS, Canada
Ravi Ramjeesingh , Samina Nazarali , Margaret Sheridan , Peiran Sun , Aimee Popovacki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 660)
DOI
10.1200/JCO.2024.42.3_suppl.660
Abstract #
660
Poster Bd #
L9
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Impact of nab-paclitaxel-based second-line chemotherapy on the outcomes of pancreatic cancer.
First Author: Neelakanta Dadi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
KRAS mutation status in the prediction of pancreatic tumor response after neoadjuvant systemic therapy and magnetic resonance-guided SBRT.
First Author: Amit Jethanandani
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Vascular resection for pancreas cancer: Ten-year real-world experience from a single high-volume center.
First Author: David Henault
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of site of metastases in pancreatic ductal adenocarcinoma.
First Author: Adeel Arshad